| MOQ: | 1000 pièces |
| Prix: | USD |
| Standard Packaging: | 1 pièces/boîte, 50 pièces/boîte, 100 pièces/boîte |
| Delivery Period: | selon la quantité commandée |
| Méthode De Paiement: | LC, T/T |
| Supply Capacity: | 50,000pcs par mois |
Breakthrough new generation technology for cervical cancer screening that directly detects cancer cells and cervical cancer lesions.
Unlike traditional cervical cancer screening methods (TCT and HPV) that detect abnormal cells or HPV virus, our test assay directly identifies cancerous cells and cervical cancer lesions through E7 oncoprotein detection.
When E7 oncoprotein is expressed in large quantities, it causes cells to develop high-grade precancerous lesions until cancerous. Detection of E7 helps evaluate cervical precancerous lesions.
Direct Detection: Use E7 oncoprotein rapid kit at hospitals, clinics, or for home testing to detect cervical cancer.
Combined with TCT/Pap Smear: Use E7 to further evaluate precancerous progression when only TCT testing is available.
Combined with HPV DNA Test: Improves diagnosis specificity of cervical lesions and provides referral basis for colposcopy.
For Positive TCT/HPV DNA Patients: Identify transient infections and assess disease progression risk.
Post-Surgery Patients: Assess recurrence risk and prognosis.
For Negative TCT/HPV DNA Patients: Detect lesions to avoid missed diagnosis when DNA tests show weak or false negatives.
Cervical Exfoliated Cell Sample Extraction:
| MOQ: | 1000 pièces |
| Prix: | USD |
| Standard Packaging: | 1 pièces/boîte, 50 pièces/boîte, 100 pièces/boîte |
| Delivery Period: | selon la quantité commandée |
| Méthode De Paiement: | LC, T/T |
| Supply Capacity: | 50,000pcs par mois |
Breakthrough new generation technology for cervical cancer screening that directly detects cancer cells and cervical cancer lesions.
Unlike traditional cervical cancer screening methods (TCT and HPV) that detect abnormal cells or HPV virus, our test assay directly identifies cancerous cells and cervical cancer lesions through E7 oncoprotein detection.
When E7 oncoprotein is expressed in large quantities, it causes cells to develop high-grade precancerous lesions until cancerous. Detection of E7 helps evaluate cervical precancerous lesions.
Direct Detection: Use E7 oncoprotein rapid kit at hospitals, clinics, or for home testing to detect cervical cancer.
Combined with TCT/Pap Smear: Use E7 to further evaluate precancerous progression when only TCT testing is available.
Combined with HPV DNA Test: Improves diagnosis specificity of cervical lesions and provides referral basis for colposcopy.
For Positive TCT/HPV DNA Patients: Identify transient infections and assess disease progression risk.
Post-Surgery Patients: Assess recurrence risk and prognosis.
For Negative TCT/HPV DNA Patients: Detect lesions to avoid missed diagnosis when DNA tests show weak or false negatives.
Cervical Exfoliated Cell Sample Extraction: